MeaneyCJ,BeccariMV,YangY,ZhaoJ, 2017.Systematic Review and Meta Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia,Pharmacotherapy 37 401 -11
McCulloughPA,BeaverTM,Bennett-GuerreroE,EmmettM,FonarowGC,GoyalA, 2014.Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management,Rev Cardiovasc Med 15 11 -23
HaganAE,FarringtonCA,WallGC,BelzMM, 2016.Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study,Clin Nephrol 85 38 -43
YuMY,YeoJH,ParkJS,LeeCH,KimGH, 2017.Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients,PloS one 12 e0173542 -
LepageL,DufourAC,DoironJ,HandfieldK,DesforgesK,BellR, 2015.Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD,Clin J Am Soc Nephro 10 2136 -42
ChaitmanM,DixitD,BridgemanMB, 2016.Potassium-binding agents for the clinical management of hyperkalemia, 41 43 -
LiL,HarrisonSD,CopeMJ,ParkC,LeeL,SalaymehF, 2016.Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia,J Cardiovasc Pharm T 21 456 -65
ChenCC,ChenCA,ChauT,LinSH, 2005.Hypokalaemia and hypomagnesaemia in an oedematous diabetic patient with advanced renal failure,Nephrol Dial Transpl 20 2271 -73
PittB,AnkerSD,BushinskyDA,KitzmanDW,ZannadF,HuangIZ, 2011.Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebocontrolled study in patients with chronic heart failure (the PEARL-HF) trial,Eur Heart J 32 820 -28
NepalM,BucaloiuID,NorfolkER, 2010.Hypernatremia in a patient treated with sodium polystyrene sulfonate,Int J Nephrol Renovasc Dis 3 141 -
FilippiL,CecchiA,DaniC,BertiniG,PezzatiM,RubaltelliFF, 2004.Hypernatraemia induced by sodium polystyrene sulphonate (Kayexalate®) in two extremely low birth weight newborns,Pediatr Anesth 14 271 -75
CherninG,Gal OzA,Ben AssaE,SchwartzIF,WeinsteinT,SchwartzD, 2012.Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin Angiotensin Aldosterone System Inhibition Therapy,Clin Cardiol 35 32 -36
KakajiwalaA,BartonKT,RampollaE,BreenC,Pradhan M. Acute, 2017.Hypocalcemia and Metabolic Alkalosis in Children on Cation-Exchange Resin Therapy,Case Rep Nephrol Dial -
BatterinkJ, 2015.Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia,Can J Hosp Pharm 68 296 -303
MistryM.,SheaA.,GiguereP, 2016.Evaluation of sodium polystyrene sulfonate dosing strategies in the inpatient management of hyperkalemia,Ann Pharmacother 50 455 -62
HarelZ,HarelS,ShahPS, 2013.Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review,Am J Med 126 264e9 -264e24
MountDB,KasperD,FauciA,HauserS,McGraw Hill Education, 2015.Potassium disorders,Harrison's Principles of Internal Medicine 295 -312
Lillemoe K.D.,RomoloJ.L.,HamiltonS.R., 1987.Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis,Surgery 101 267 -72